- Home
- ALGS vs ANL Comparison
ALGS vs ANL Comparison
Compare ALGS & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALGS | ANL |
|---|---|---|
| Founded | 2018 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.2M | 62.0M |
| IPO Year | 2020 | 2023 |
Fundamental Metrics
Financial Performance| Metric | ALGS | ANL |
|---|---|---|
| Price | $8.19 | $3.67 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 1 |
| Target Price | ★ $46.67 | N/A |
| AVG Volume (30 Days) | 79.7K | ★ 1.3M |
| Earning Date | 03-09-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,646,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.76 | $0.88 |
| 52 Week High | $30.02 | $3.86 |
Technical Indicators
Market Signals| Indicator | ALGS | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 43.31 | 85.45 |
| Support Level | $7.92 | $1.63 |
| Resistance Level | $9.13 | $1.93 |
| Average True Range (ATR) | 0.91 | 0.32 |
| MACD | -0.01 | 0.22 |
| Stochastic Oscillator | 15.97 | 82.75 |
Price Performance
Historical ComparisonAbout ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.